ArticlePPAR research2009
PPARγ2 polymorphism and human health.
Article in PPAR research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- A Rapid Genotyping Assay forCurrent developments in nutrition · 2026Article
- DIFFERENCES BETWEEN AQUEOUS HUMOR AND SERUM CONCENTRATIONS OF BDNF AND PPARG GENETIC VARIANTS IN GLAUCOMA PATIENTS.Acta clinica Croatica · 2025Review
- Genetic Associations ofDiagnostics (Basel, Switzerland) · 2024Article
- Genetic polymorphism of Pro12Ala in type 2 diabetes mellitus: Role in inflammation linked to Insulin resistance.Bioinformation · 2023Article
- Analysis of key genes and pathways in breast ductal carcinomaOncology letters · 2020Article
- Is the rs1801282 (G/C) Polymorphism ofOpen access Macedonian journal of medical sciences · 2018Article
- Variant Alleles of theFrontiers in endocrinology · 2018Article
- Relationship ofOncoTargets and therapy · 2018Article
- Article
- Probing the role of PPARγ in the regulation of late-onset Alzheimer's disease-associated genes.PloS one · 2018Article
- Nutrigenomic Functions of PPARs in Obesogenic Environments.PPAR research · 2016Review
- Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?PPAR research · 2015Review
- Peroxisome proliferator-activated receptor gamma rs1801282 C>G polymorphism is associated with polycystic ovary syndrome susceptibility: a meta-analysis involving 7,069 subjects.International journal of clinical and experimental medicine · 2015Article
- Peroxisome proliferator-activated receptor gamma (PPARG) polymorphisms and breast cancer susceptibility: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Genetic characterization of Greek population isolates reveals strong genetic drift at missense and trait-associated variants.Nature communications · 2014Article
- Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?PPAR research · 2013Article
- Does Pro(12)Ala Polymorphism Enhance the Physiological Role of PPARγ2?PPAR research · 2013Article
- Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases.World journal of gastroenterology · 2010Article
- PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues.PPAR research · 2010Article
- Regulation of Translational Efficiency by Disparate 5' UTRs of PPARgamma Splice Variants.PPAR research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nuclear hormone receptor peroxisome proliferator activated receptor gamma (PPARγ) is an important transcription factor regulating adipocyte differentiation, lipid and glucose homeostasis, and insulin sensitivity. Numerous genetic mutations of PPARγ have been identified and these mutations positively or negatively regulate insulin sensitivity. Among these, a relatively common polymorphism of PPARγ, Pro12Ala of PPARγ2, the isoform expressed only in adipose tissue has been shown to be associated with lower body mass index, enhanced insulin sensitivity, and resistance to the risk of type 2 diabetes in human subjects carrying this mutation. Subsequent studies in different ethnic populations, however, have revealed conflicting results, suggesting a complex interaction between the PPARγ2 Pro12Ala polymorphism and environmental factors such as the ratio of dietary unsaturated fatty acids to saturated fatty acids and/or between the PPARγ2 Pro12Ala polymorphism and genetic factors such as polymorphic mutations in other genes. In addition, this polymorphic mutation in PPARγ2 is associated with other aspects of human diseases, including cancers, polycystic ovary syndrome, Alzheimer disease and aging. This review will highlight findings from recent studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.